Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 21,831 shares of the stock in a transaction on Monday, October 21st. The stock was sold at an average price of $5.61, for a total transaction of $122,471.91. Following the completion of the sale, the insider now owns 663,550 shares in the company, valued at approximately $3,722,515.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Matthew Link also recently made the following trade(s):
- On Friday, October 18th, Matthew Link sold 20,487 shares of Sight Sciences stock. The shares were sold at an average price of $5.98, for a total transaction of $122,512.26.
- On Wednesday, October 16th, Matthew Link sold 20,734 shares of Sight Sciences stock. The stock was sold at an average price of $5.91, for a total value of $122,537.94.
Sight Sciences Stock Down 7.5 %
Shares of Sight Sciences stock opened at $5.52 on Tuesday. Sight Sciences, Inc. has a 52-week low of $1.04 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. The business's 50 day simple moving average is $6.31 and its 200 day simple moving average is $6.30. The firm has a market cap of $277.71 million, a PE ratio of -5.16 and a beta of 2.71.
[625,000% Gain] – Are You Ready for the Next Altcoin Boom?
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The business had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.32 million. During the same quarter last year, the firm earned ($0.30) earnings per share. On average, analysts predict that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the company. Lake Street Capital assumed coverage on Sight Sciences in a research report on Wednesday, August 21st. They set a "buy" rating and a $10.00 price target on the stock. Morgan Stanley raised their target price on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an "equal weight" rating in a report on Monday, July 15th. Citigroup upped their price target on shares of Sight Sciences from $6.00 to $6.50 and gave the company a "neutral" rating in a report on Wednesday, July 10th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Sight Sciences in a research report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $7.25.
View Our Latest Research Report on Sight Sciences
Institutional Trading of Sight Sciences
Hedge funds and other institutional investors have recently modified their holdings of the stock. Steele Capital Management Inc. acquired a new position in Sight Sciences during the second quarter valued at approximately $67,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Sight Sciences in the 1st quarter valued at approximately $59,000. SG Americas Securities LLC bought a new position in shares of Sight Sciences in the third quarter valued at $75,000. The Manufacturers Life Insurance Company acquired a new position in Sight Sciences during the second quarter worth $95,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Sight Sciences by 51.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company's stock worth $141,000 after acquiring an additional 9,106 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company's stock.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
